2 Amendments of Alessandra MORETTI related to 2019/2816(RSP)
Amendment 76 #
Subheading 1 a (new)
Ia. whereas any measure regarding the environmental impact of drugs shall consider as the prevailing principle the right of the patients to a swift access to drugs deemed safe and effective with respect to the current risk-benefit assessment criteria;
Amendment 159 #
Paragraph 16
16. Considers that the environmental impacts of pharmaceuticals could be included into the benefit-risk assessment of human medicines, as is already the case for veterinary medicines, while making sure that no delay occurs in the marketing authorization procedure of drugs deemed suitable in accordance with the current criteria of the assessment itself, so as to guarantee prompt access to safe and effective pharmacological treatments for patients;